Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs

Documenti analoghi

• Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma
  di: Shinsuke Uchikawa, et al.
  Pubblicazione: (2024)
• Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma
  di: Takahiro Kinami, et al.
  Pubblicazione: (2024)
• Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution
  di: Yuri Mitamura, et al.
  Pubblicazione: (2025)
• Editorial comment to “Recurrent episodes of atrioventricular nodal reentrant tachycardia: Sites of ablation success, ablation endpoint, and primary culprits for recurrence”
  di: Shiro Nakahara, et al.
  Pubblicazione: (2024)
• Deciphering the dual nature of the Fibrosis‐4 index in predicting hepatocellular carcinoma risk among hepatitis B patients undergoing nucleos(t)ide analog therapy
  di: Jun Arai, et al.
  Pubblicazione: (2024)